Developments in the production and quality control of poliovirus vaccines - Historical perspectives

Biologicals

Volumn 34, Issue 2, 2006, Pages 87-90

  Furesz, J ^a  

^a HEALTH CANADA   (Canada)

Author keywords

Inactivated poliovirus vaccine; Live oral poliovirus vaccine; Preparation of poliovirus vaccines; Quality control testing of poliovirus vaccines

Indexed keywords

INACTIVATED VACCINE; ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INCIDENCE; NONHUMAN; POLIOMYELITIS; PRIORITY JOURNAL; QUALITY CONTROL; TISSUE CULTURE; VACCINE PRODUCTION; VIRUS ATTENUATION; WORLD HEALTH ORGANIZATION;

ANIMALS; CHILD; HAPLORHINI; HUMANS; POLIOVIRUS VACCINES; QUALITY CONTROL;

POLIOVIRUS;

EID: 33646811190     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2006.02.008     Document Type: Article

References (26)

1. Enders J.F., Weller T.H., and Robbins F.C. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109 (1949) 85-87
2. Robbins FC. The history of polio vaccine development. In: Plotkin SA, Orenstein WA: Vaccines 4th ed. Saunders; 2004. p. 17-30.
3. Francis Jr. T. Evaluation of the 1954 field trial of poliomyelitis vaccine (1957), Edwards Brothers/National Foundation of Infantile Paralysis, Ann Arbor, Mich
4. Nathanson N., and Langmuir A.D. The Cutter incident: poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. I. Background. Am J Hyg 78 (1963) 16-28
5. Nathanson N., and Langmuir A.D. The Cutter incident: poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. Am J Hyg 78 (1963) 29-60
6. Nathanson N., and Langmuir A.D. The Cutter incident: poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. III. Comparison of the clinical character of vaccinated and contact cases occurring after use of high-rate lots of Cutter vaccine. Am J Hyg 78 (1963) 61-80
7. U.S. Public Health Service Technical Report on Salk poliomyelitis vaccine (1955), Public Health Service, Rockville, MD
8. Melnick J.L. Virus inactivation: lessons from the past. Dev Biol Stand 75 (1990) 29-36
9. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine - live, in: Plotkin SA, Orenstein WA: Vaccines 4th ed. Saunders; 2004. p. 651-705.
10. Eddy B.E., Borman G.S., Berkeley W.H., and Young R.D. Tumors induced in hamsters by injection of rhesus monkey kidney cell extracts. Proc Soc Exp Biol Med 107 (1961) 191-197
11. Mortimer E.A., Lepow M.L., Gold E., Robbins F.C., Burton G.J., and Fraumeni Jr. J.F. Long-term follow-up of persons inadvertently inoculated with SV40 as neonates. N Engl J Med 305 (1981) 1517-1518
12. Shah K., and Nathanson N. Human exposure to SV40: review and comment. Am J Epidemiol 103 (1976) 1-12
13. Requirements for poliomyelitis vaccine, oral. WHO Technical Report Series No. 273;1962; No. 687;1983; No. 800;1990; No. 897;2000 ; No. 904;2002.
14. van Wezel A.L. Growth of cell-strains and primary cells on micro-carriers in homogenous culture. Nature 216 (1967) 64-65
15. von Siefried A., Chun J.H., Orant J.A., Letvenuk L., and Pearson E.W. Inactivated poliovirus vaccine and test development at Connaught Laboratories Ltd. Rev Infect Dis 6 Suppl. 2 (1984) S345-S349
16. van Wezel A.L., van Steenis G., van der Marel P., and Osterhaus A.D.M.E. Inactivated poliovirus vaccine: current production and new developments. Rev Infect Dis 6 Suppl. 2 (1984) S335-S340
17. Montagnon B.J., Fanget B., and Vincent-Falquet J.C. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev Infect Dis 6 Suppl. 2 (1984) S341-S344
18. Duchene M., Peetermans J., D'Hondt E., Harford N., Fabry L., and Stephenne J. Production of poliomyelitis vaccines: past, present and future. Viral Immunol 3 (1990) 243-272
19. Koprowski H., Jervis G.A., and Norton T.W. Immune response in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis virus. Am J Hyg 55 (1952) 108-126
20. Payne A.M.M. Field safety and efficacy of live attenuated poliovirus vaccines. Poliomyelitis: papers and discussions. Presented at the 5th international poliomyelitis conference (1961), JD Lipincott, Philadelphia 257-261
21. WHO Expert Committee on Poliomyelitis. WHO Technical Report Series No. 203;1960.
22. Cockburn W.C. The work of the WHO Consultative Group on poliomyelitis vaccines. Bull World Health Organ 66 (1988) 143-154
23. Furesz J., and Contreras G. Some aspects of the monkey neurovirulence test used for the assessment of oral poliomyelitis vaccines. Dev Biol Stand 78 (1993) 61-70
24. WHO Consultative Group. Evidence on the safety and efficacy of live poliomyelitis vaccines currently in use, with special reference to type 3 poliovirus. Bull World Health Organ 40 (1969) 925-945
25. Esteves K. Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ 66 (1988) 739-746
26. Dragunski E., Nomura T., Karpinski K., Furesz J., Wood D.J., Pervikov Y., et al. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study. Bull World Health Organ 81 (2003) 251-260